Janssen and BMS to Test Darzalex, Opdivo Combo in Multiple Myeloma and Solid Tumors
Janssen Biotech and Bristol-Myers Squibb will collaborate in a…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Myeloma Triple Combo Treatment Found Superior to Standard Therapy in Phase 3 Trial
Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy…
Myeloma Resistance to Proteasome Inhibitors May Boost Sensitivity to Other Drug Classes
Researchers have discovered a mechanism underlying the development of…
CTCA Hospitals Enrolling Myeloma, Other Cancer Patients, in TAPUR Clinical Trial
Cancer Treatment Centers of America (CTCA) recently began enrolling…
Triple-Combo Treatment of Smoldering Multiple Myeloma May Stall Disease Progression
Early treatment with a combination of anti-cancer drugs in…
Specialty US Pharmacy, Diplomat, to Dispense Darzalex Combo to Advanced Myeloma Patients
The monoclonal antibody Darxalex (daratumumab) was recently approved by…
